Physician

Lucio Navarro Gordan, MD

According to 2025 Medicare claims, Lucio Gordan, MD (NPI: 1346235975) practices hematology/oncology in the Gainesville, FL market, with the plurality of this provider's patient population coming from Alachua, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32605-4308.

Gordan's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 718 traditional Medicare patients, billed 213,728 HCPCS/CPT codes, and received $3,914,102 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,319 prescription claims across 181 beneficiaries totaling $4,319,881 in drug costs, led by Xtandi (Enzalutamide). DME data shows 39 claims. Open Payments data shows 42 records totaling $127,482. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $4,752,523 to $3,914,102. In contrast, Part D prescription costs have risen steadily, from $2,204,025 to $4,319,881. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $29,640 to $544.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,426	456,147	$4,752,523
2016	1,438	529,175	$5,813,408
2017	1,341	386,358	$6,223,602
2018	1,214	460,795	$5,718,985
2019	1,090	412,383	$4,933,713
2020	735	339,162	$4,186,917
2021	687	266,949	$4,069,130
2022	718	251,749	$3,812,888
2023	732	207,115	$3,807,559
2024	718	213,728	$3,914,102

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	307	1,852	$2,204,025
2016	265	1,831	$2,662,763
2017	291	1,778	$2,629,754
2018	265	1,787	$2,729,414
2019	214	1,470	$2,997,176
2020	184	1,376	$3,034,967
2021	196	1,287	$2,355,131
2022	200	1,277	$2,867,512
2023	185	1,228	$3,173,311
2024	181	1,319	$4,319,881

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	98	621	$86,555
2016	46	379	$61,915
2017	N/R	151	$18,550
2018	N/R	112	$9,173
2019	N/R	105	$12,172
2020	N/R	31	$3,230
2021	N/R	89	$6,674
2022	N/R	62	$3,600
2023	N/R	52	$9,370
2024	N/R	39	$810

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	446	943	$93
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	170	241	$13
96372	Injection of drug or substance under skin or into muscle	115	484	$11
36415	Insertion of needle into vein for collection of blood sample	583	1,831	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	590	1,959	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	61	1,830	$848,083
Pomalyst	Pomalidomide	24	672	$521,889
Brukinsa	Zanubrutinib	37	1,110	$479,165
Revlimid	Lenalidomide	19	511	$338,257
Venclexta	Venetoclax	25	732	$239,535

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	13	$421
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	14	$263
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	12	$125

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	29	$5,937	Janssen Biotech, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	13	$121,545	Janssen Scientific Affairs, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Lucio Navarro Gordan, MD?

Tedicare shows public-source Medicare data for Lucio Navarro Gordan, MD (NPI 1346235975), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Lucio Navarro Gordan, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Lucio Navarro Gordan, MD?

Lucio Navarro Gordan, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Lucio Navarro Gordan, MD have Open Payments data?

Lucio Navarro Gordan, MD has 42 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.